Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397463 | 0.74 | GPR119 (0.50) | MEN1KMT2ACHRM3ALDH1A1 | |
| SCHEMBL20707105 | 0.74 | CHRM3 (0.46) | CYP2D6HRH1CHRM3CHRM2CHRM1 | |
| Tert-Butylbenzene SCHEMBL28078162 | 0.74 | HTR3A (0.47) | MEN1KMT2ALMNACYP2D6HRH1 | |
| SCHEMBL24319363 | 0.72 | CHRNB2 (0.31) | — | |
| SCHEMBL9202300 | 0.72 | CHRM2 (0.46) | MEN1KMT2ALMNACYP2D6HRH1 | |
| SCHEMBL2697321 | 0.72 | CYP2B6 (0.66) | MEN1KMT2ALMNACYP2D6HRH1 | |
| SCHEMBL3393147 | 0.71 | CACNA2D1 (0.50) | CHRM3HTT | |
| SCHEMBL4125494 | 0.70 | CYP2B6 (0.41) | MEN1KMT2ALMNACHRM3CHRM2 | |
| SCHEMBL4278766 | 0.70 | CHRM3 (0.46) | MEN1KMT2ACHRM3CHRM2CHRM1 | |
| SCHEMBL2431449 | 0.69 | CYP2B6 (0.43) | MEN1KMT2ALMNACYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| EP-1784401-A4 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD (CA) | 2009-07-15 | — | — | EP | disclosed |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-11 | — | — | US | disclosed |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-11 | — | — | US | disclosed |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-11 | — | — | US | disclosed |
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-7378420-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-05-27 | — | — | US | disclosed |
| US-7378420-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-05-27 | — | — | US | disclosed |
| US-7378420-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-05-27 | — | — | US | disclosed |
| EP-1784401-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2007-05-16 | — | — | EP | disclosed |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006024160-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ORAI1, ATP2A1, CACNA1B | MEN1 4504/4885KMT2A 2878/4885LMNA 1657/4885 |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | ORAI1, ATP2A1, CACNA1B | MEN1 4504/4885KMT2A 2878/4885LMNA 1657/4885 |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ORAI1, ATP2A1, CACNA1B | MEN1 4504/4885KMT2A 2878/4885LMNA 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.